The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
1
The Kirby Institute, UNSW Sydney, High Street, Sydney, New South Wales 2052, Australia. Electronic address: tapplegate@kirby.unsw.edu.au.
2
Médecins Sans Frontières Access Campaign, Rue de Lausanne 78 P.O Box 1016, Geneva CH-1211, Switzerland.
3
Clinton Health Access Initiative, 383 Dorchester Avenue Suite 400, Boston, MA 02127, USA.
Abstract
The world has embraced the call for global elimination of hepatitis C virus by 2030. The unprecedented speed of therapeutic development and increased access to direct-acting antivirals has made elimination a possibility. We must screen hundreds of millions of people to diagnose and treat those currently infected. Global access to hepatitis C virus diagnostics will be a keystone to success. Key challenges must be overcome and systems optimized to ensure widespread access to existing diagnostics. Although promising technologies may soon transform the landscape, innovative strategies are needed to stimulate investment and accelerate the development of point-of-care hepatitis C virus diagnostics.